Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection Fraction

Not yet recruiting

• Conditions: Heart Failure; Preserved Ejection Fraction

• Registration Number: NCT07047508
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

The main objective of the study is to describe the effectiveness and safety outcomes among Chinese hospitalized heart failure with preserved ejection fraction (HFpEF) patients initiating Jardiance® in the real-world setting.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-06
• Study First Submitted: 2025-06-24
• Study First Submitted QC: 2025-06-24
• Last Update Submitted: 2025-06-24
• Study Start: 2025-06-30
• Study First Posted: 2025-07-02
• Last Update Posted: 2025-07-02
• Primary Completion: 2026-03-31
• Study Completion: 2026-03-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of the composite outcome of HHF (the first HHF after the index date) or CV death	up to 2.5 years	HHF=Hospitalization for Heart Failure CV=cardiovascular

Secondary Outcome Measures

Name	Time	Method
Incidence of CV death	up to 2.5 years
Occurrence of death from any cause	up to 2.5 years
Incidence of the HHF (the first HHF after the index date)	up to 2.5 years